Heart failure has been shown to be a contributing factor in more deaths in rural vs urban counties in which cardiovascular disease was pinpointed as the underlying cause of death.
Heart failure has been shown to be a contributing factor in more deaths in rural vs urban counties in which cardiovascular disease (CVD) was pinpointed as the underlying cause of death from January 1, 2011, to December 31, 2018, according to study findings published in PLoS One.
Previous research has not put an exact number on the disparity between heart failure–related deaths in urban and rural counties, the authors highlight, even though “cardiovascular disease is more prevalent among adults living in rural US counties than those in urban counties, and that deaths attributed to heart failure have risen nationwide since 2011,” according to a statement on the findings.
For their study, the investigators from Northwestern University’s Feinberg School of Medicine culled county-level data from the CDC’s Wide-Ranging Online Data for Epidemiologic Research Multiple Cause of Death Online Database. Adults aged 35 to 64 years and 65 to 84 years from all 50 states and the District of Columbia whose primary and secondary causes of death were CVD and heart failure, respectively, were included.
Overall, larger increases were seen in younger adults (aged 35-64 years) compared with older adults (aged 65-84 years), with the rural vs urban county difference especially notable in the South and primarily affected by socioeconomic and clinical risk factors. Broken down by race/ethnicity, young Black men had the largest annual mortality increase: 6.1% (95% CI, 3.7%-8.5%).
The research also revealed these findings:
County-level data were provided by the US Census Bureau Population and Housing Unit Estimates, Small Area Income and Poverty Estimates Program, Small Area Health Insurance Estimates Program files, US Bureau of Labor Statistics Local Area Unemployment Statistics file, CDC Behavioral Risk Factor Surveillance System, and the Health Resources and Services Administration Area Health Resources File.
The authors note that their findings are especially important because they highlight the ever-increasing gap between rural and urban counties for heart failure–related deaths, especially in the South, and show a correlation with that region of the United States and its higher rates of diabetes and obesity.
They also identify a great need for community-level prevention efforts, as well as highlight social and economic differences in the 2 county types, including that rural counties experience disproportionately higher rates of hospital closures.
Future studies should investigate the effects of the Affordable Care Act on heart failure–related mortality rates and access to physicians and hospitals, because hospital closure rates have been lower in states that expanded Medicaid coverage. Investigators should also examine differences in heart failure–related mortality in smaller areas.
“Differences in county-level factors may account for a significant amount of the observed variation in heart failure–related mortality between rural and urban counties,” the authors concluded. “Efforts to reduce the rural-urban disparity in heart failure–related mortality rates will likely require diverse public health and clinical interventions targeting the underlying causes of this disparity.”
Reference
Pierce JB, Shah NS, Petito LC, et al. Trends in heart failure-related cardiovascular mortality in rural versus urban United States counties, 2011–2018: a cross-sectional study. PLoS One. Published online March 3, 2021. doi:10.1371/journal.pone.0246813
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
2 Commerce Drive
Cranbury, NJ 08512